Blood

Vol. 148, Issue 5 Issue 5 2026
18
Articles

Articles in this Issue

Microclone with megaimpact

Jayastu Senapati, Naval G. Daver Jul 30, 2026 pp. 529-530 10.1182/blood.2026034528

Biallelic loss-of-function mutations in <i>BPNT1</i> cause vitamin B12–dependent megaloblastic anemia

Yi-Heng Zeng, Yun-Hong Li, Ru-Ying Yuan et al. Jul 30, 2026 pp. 634-638 10.1182/blood.2026033550

Abstract We identified biallelic loss-of-function BPNT1 mutations in 3 patients with recurrent vitamin B12–dependent megaloblastic anemia. Mechanistically, BPNT1 deficiency caused...

Single-cell MRD: from detection to direction

Chong Chyn Chua Jul 30, 2026 pp. 523-524 10.1182/blood.2026033927

MLL3 and MLL4 sustain hematopoietic stem cell multipotency by opposing a B-cell default state

Helen C. Wang, Ran Chen, Wei Yang et al. Jul 30, 2026 pp. 560-573 10.1182/blood.2025032969

Abstract Hematopoietic stem cells (HSCs) and multipotent progenitors (MPPs) are sustained by networks of transcription factors and epigenetic regulators that prime lineage-specific...

Crumpled cytoplasm, clear diagnosis: the iconic morphology of Gaucher disease

Derek C. Sung, Dale M. Frank Jul 30, 2026 pp. 639-639 10.1182/blood.2026034468

Inhibition of high CXCR4 with motixafortide and absence of single-cell MRD predict outcome after AML consolidation

Enise Ceran, Sonia Jaramillo Segura, Anne Kathrin Merbach et al. Jul 30, 2026 pp. 545-559 10.1182/blood.2025032033

Abstract Relapse after remission remains the primary cause of treatment failure in acute myeloid leukemia (AML), underscoring the need for strategies to eliminate residual leukemic...

Prognostic impact of <i>FLT3</i> -ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy

Nicolas Duployez, Romane Joudinaud, Augustin Boudry et al. Jul 30, 2026 pp. 598-609 10.1182/blood.2025032829

Abstract FLT3 internal tandem duplications (FLT3-ITD) are major genetic events in acute myeloid leukemia (AML). Although the clinical impact of FLT3-ITD “macroclones” (allelic rati...

Chronic pain in sickle cell disease: a role for lysophosphatidic acid

Viacheslav Viatchenko-Karpinski, Iryna A. Khasabova, Malcolm Johns et al. Jul 30, 2026 pp. 623-633 10.1182/blood.2025031738

Abstract Sickle cell disease (SCD) is a hereditary hemoglobinopathy characterized by persistent pain. The mechanisms underlying pain in SCD are poorly understood, and opioids remai...

Promises and potential pitfalls of in vivo CAR gene therapy

Dimitrios L. Wagner, Magdi Elsallab, Marcela V. Maus Jul 30, 2026 pp. 535-544 10.1182/blood.2025031898

Abstract Genetically modified T cells expressing chimeric antigen receptors (CARs) manufactured ex vivo have demonstrated high efficacy in patients with lymphoid hematologic malign...

To deplete or not to deplete: that is the question

Dimitrios Mougiakakos Jul 30, 2026 pp. 526-527 10.1182/blood.2026034891

Neonatal platelets: MDSC-ooling the monocytes

Yunfeng Liu, Karina Yazdanbakhsh Jul 30, 2026 pp. 531-532 10.1182/blood.2026034150

Neonatal platelets differentiate monocytes to a myeloid-derived suppressor cell phenotype

Preeti Maurya, Daniel O’Reilly, Zachary T. Hilt et al. Jul 30, 2026 pp. 610-622 10.1182/blood.2025028734

Abstract Adult platelets are relatively enriched in immune-related molecules compared with neonatal platelets, but neonatal platelets express some growth factors and enzymes at com...

Domostegui A, Peddigari S, Mercer CA, et al. Impaired ribosome biogenesis checkpoint activation induces p53-dependent MCL-1 degradation and MYC-driven lymphoma death. <i>Blood</i> . 2021;137(24):3351-3364.

Jul 30, 2026 pp. 640-640 10.1182/blood.2026035133

Tunneling nanotube–mediated intercellular filamin A transport mechanosensitively programs osteoclastogenesis in myeloma bone disease

Jing Guo, Jingjing Wang, Ying Xie et al. Jul 30, 2026 pp. 581-597 10.1182/blood.2025031627

Abstract Intercellular communication between multiple myeloma (MM) cells and osteoclast precursor cells (pre-OCs) contributes extensively to the occurrence and development of myelo...

Lipids drive chronic sickle cell disease pain

Katelyn E. Sadler Jul 30, 2026 pp. 532-533 10.1182/blood.2026034092

Nanotube trafficking fuels myeloma bone loss

Evangelos Terpos, Maria Gavriatopoulou Jul 30, 2026 pp. 527-528 10.1182/blood.2026034120

Epigenetic toggling between multipotency and differentiation

Emery H. Bresnick Jul 30, 2026 pp. 524-525 10.1182/blood.2026034529

CD19 CAR T-cell therapy is feasible for patients with pemphigus vulgaris treated without lymphodepletion in the RESET-PV trial

Daniel Nunez, Jason Stadanlick, Thomas Furmanak et al. Jul 30, 2026 pp. 574-580 10.1182/blood.2025032093

Abstract Lymphodepleting preconditioning (LD) is essential for the efficacy of chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies. However, in the setting o...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page